COVID-19 Updates

Visit UC San Diego's Coronavirus portal for the latest information for the campus community.

  • The Health Sciences Sponsored Project Pre-Award Office will remain open and operational and will continue to provide service to our department partners, faculty, academics, physicians, and scholars. Because of the evolving situation with COVID-19 and because the health and welfare of our staff and their families is of highest priority, we are providing our teams with the flexibility they need in terms of telecommuting while maintaining our commitment to our clients and the organization. We expect some adjustments as we adapt to operating in these uncertain and rapidly changing times, and we appreciate and thank you for your understanding and patience. Please note, these workplace adjustments will not impact your ability to reach out to your current HS SPPO contacts who will continue to be available to help. 
If you have any questions, please e-mail eswilson@health.ucsd.edu

+ Expand All
  • NIH-Wide Strategic Plan for COVID-19 Research  (7/13/2020)
  • COVID-19 Information for NIH Applicants and Recipients
  • COVID-19 FAQs for COVID-19 Flexibilities for Applicants and Recipients
    •  Update: Effective October 1, 2020, the flexibility for recipients to continue charging salaries and benefits to active NIH awards consistent with the recipients' policy of paying salaries (under unexpected or extraordinary circumstances), has ended. Any requests after that date will be considered by the funding IC on a case by case basis.  As a reminder, recipients must maintain appropriate records and cost documentation in order to substantiate the charging of any salaries and other project activities costs related to interruption of operations or services. 
  • Update on COVID-19 Flexibilities for the Research Community on YouTube (posted 3/26/2020)
    • Dr. Mike Lauer, NIH Deputy Director for Extramural Research, provides updates for the research community on flexibilities NIH is providing the community due to the COVID-19 public health emergency.
    •  
  • NIH Message to Applicants and Recipients of NIH Funds on Flexibilities Needed for COVID-19 on YouTube (posted 3/17/2020)
    • Dr. Mike Lauer, NIH Deputy Director for Extramural Research, provides an update for applicants and recipients of federal funding on flexibilities NIH has put in place to support them and their research through the disruptions caused by COVID-19.
    •  
Notices
NOT-GM-20-026
Guidance for Cost-Related Flexibilities Available to Support of Competitive Research (SCORE) Award Recipients Affected by COVID-19
​NOT-OD-20-088
Flexibilities for Assured Institutions for Activities of Institutional Animal Care and Use Committees (IACUCs) Due to COVID-19
​NOT-OD-20-087
Guidance for NIH-funded Clinical Trials and Human Subjects Studies Affected by COVID-19
​NOT-OD-20-086
Flexibilities Available to Applicants & Recipients of Federal Financial Assistance Affected by COVID-19
​NOT-OD-20-083
General FAQs - Proposal Submission and Award Management Related to COVID-19
​NOT-CA-20-054
Notice of Information: Contributing to the Global COVID-19 Crisis Response by Allowing Some NCI-supported Projects to be Redirected to COVID-19-related Research During the Crisis
​NOT-MH-20-061
Notice Announcing the Availability of Common Data Elements for Research Related to the Public Health Emergency caused by Coronavirus Disease 2019 (COVID-19)
​NOT-OD-20-118
Guide Notice of Information Highlighting Harmonization and Data Sharing Expectations for Supplement and Revision Projects Addressing Social, Behavioral, Economic and Health Impacts of the COVID-19 Public Health Emergency
​NOT-NS-20-076
Notice to Extend Eligibility for Submission of Diversity K22 Applications due to COVID–related Disruptions
​NOT-OD-20-122
Guidance for Applicants Preparing Applications for the Fall 2020 Due Dates During the COVID-19 Pandemic
​NOT-OD-20-158
Temporary Extension of Eligibility for the NIH K99/R00 Pathway to Independence Award During the COVID-19 Pandemic
​NOT-OD-20-163
Extending the Special Exception to the NIH/AHRQ/NIOSH Post-Submission Material Policy During the COVID-19 Pandemic
​NOT-OD-20-164
Policy for Charging Personal Protective Equipment to NIH Grants and Cooperative Agreements as Direct Costs
​NOT-OD-20-179
Extending the Special Exception to the NIH/AHRQ/NIOSH Post-Submission Material Policy During the COVID-19 Pandemic: August/October 2021 Councils
​NOT-DK-20-054
Temporary Extension of Eligibility for the NIDDK K01 Mentored Research Scientist Development Award During the COVID-19 Pandemic
​NOT-AI-20-067
Notice to Extend Eligibility for Submission to PAR-19-371, NIAID Career Transition Award (K22 Independent Clinical Trial Not Allowed) due to COVID-related Disruptions
​NOT-AI-20-068
Notice to Extend Eligibility for Submission of NIAID K99 /R00 Pathway to Independence Award Applications (and Physician-Scientist K99/R00) due to COVID–related Disruptions
​NOT-OD-21-006
Exceptions to Use of a Single IRB During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency
​NOT-OD-21-026
Extended Guidance for Applicants Preparing Applications During the COVID-19 Pandemic
​NOT-OD-21-122
Guidance for Applicants Preparing Applications for the Fall 2020 Due Dates During the COVID-19 Pandemic
​NOT-OD-21-052
Reminder – Requesting Extensions for Early Career Scientists Whose Career Trajectories Have Been Significantly Impacted by COVID-19
​NOT-HL-21-009
Updated Notice of Information: NHLBI Extensions for Career Development Award (K01, K08, K23, K25) Recipients Whose Career Trajectories Have Been Significantly Impacted by COVID-19
​NOT-OD-21-095
Extending the Special Exception to the NIH/AHRQ/NIOSH Post-Submission Material Policy During the COVID-19 Pandemic: January 2022 Council


FOAs
​PA-20-163Competing Revisions to Existing NIH Grants and Cooperative Agreements (Clinical Trial Optional)
​This needs to be used in conjunction with COVID-19 specific NOSIs. This is only applicable for NIDDK and NIEHS applications. 
​PA-20-135
Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)
​This needs to be used in conjunction with COVID-19 specific NOSIs.
PA-18-935
Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement -  Clinical Trial Optional)
This needs to be used in conjunction with COVID-19 specific NOSIs.

​PA-20-272
Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
​This needs to be used in conjunction with COVID-19 specific NOSIs.
​PAR-20-256
Limited Competition Emergency Awards: Shared Personal Protective Equipment Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies (S10 Clinical Trial Not Allowed)
​The purpose of this public health emergency funding opportunity is to provide Personal Protective Equipment (PPE) to directly support the needs of the NIAID’s vaccine and treatment clinical trials and clinical studies for COVID-19. This program will ensure that adequate protective equipment is available to directly assist in safely carrying out the clinical activities and direct interactions with the patients participating in the trial. Eligibility is limited to recipients conducting COVID-related clinical research and clinical studies supported by NIAID’s emergency appropriation provided by “The Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020” and “The Coronavirus Aid, Relief and Economic Security (CARES) Act”. Due Date: applications for this limited competition FOA will be accepted on a rolling basis, beginning July 13, 2020 till July 7, 2021. 
​RFA-AA-21-003
SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R03 Clinical Trial Not Allowed)
This FOA will support research grants to address urgent, time-sensitive research questions on the relationships between alcohol consumption and COVID-19 related outcomes and consequences. The principal area of focus is research that can improve public health in the near term by informing responses to the current COVID-19 pandemic, in view of 1) the impact of alcohol misuse on incidence and severity of COVID-19 disease or 2) the effect of the COVID-19 disease and pandemic-induced restrictions on alcohol use and alcohol use disorder (AUD). Due Date: April 14, 2021. 
​RFA-AA-21-002
SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R01 Clinical Trial Not Allowed)
​This FOA will support research grants to address urgent, time-sensitive research questions on the relationships between alcohol consumption and COVID-19 related outcomes and consequences. The principal area of focus is research that can improve public health in the near term by informing responses to the current COVID-19 pandemic, in view of 1) the impact of alcohol misuse on incidence and severity of COVID-19 disease or 2) the effect of the COVID-19 disease and pandemic-induced restrictions on alcohol use and alcohol use disorder (AUD).  Due Date: April 14, 2021. 
​RFA-AA-21-004
SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R21 Clinical Trial Not Allowed)
​This FOA will support research grants to address urgent, time-sensitive research questions on the relationships between alcohol consumption and COVID-19 related outcomes and consequences. The principal area of focus is research that can improve public health in the near term by informing responses to the current COVID-19 pandemic, in view of 1) the impact of alcohol misuse on incidence and severity of COVID-19 disease or 2) the effect of the COVID-19 disease and pandemic-induced restrictions on alcohol use and alcohol use disorder (AUD).  Due Date: April 14, 2021. 
​RFA-AI-20-078
Immune Development in Early Life (IDEaL) (U19 Clinical Trial Not Allowed)
​The purpose of this Funding Opportunity Announcement is to support research to define the mechanisms regulating the establishment, development, and maintenance of immunity throughout childhood (from birth to less than 18 years of age), including the impact of pathogenic or commensal microbes or vaccination against infectious diseases, allergens, and environmental pollutants on immune ontogeny and function. This program will establish collaborations among immunologists, neonatologists, pediatricians, systems biologists, and microbiologists to expand our knowledge of the developing immune system. Knowledge obtained through this program may be applied to the design of improved vaccines and immunotherapies to combat infections or treat/prevent immune-mediated diseases in this vulnerable population. Due Date: June 4, 2021. 
​RFA-AI-20-077
Immune Development in Early Life (IDEaL) (U01 Clinical Trial Not Allowed)
​The purpose of this Funding Opportunity Announcement is to support research to define the mechanisms regulating the establishment, development and maintenance of immunity throughout childhood (from birth to less than 18 years of age), including the impact of pathogenic or commensal microbes or vaccination against infectious diseases, allergens or environmental pollutants on immune ontogeny and function. This program will establish collaborations among immunologists, neonatologists, pediatricians, systems biologists, and microbiologists to expand our knowledge of the developing immune system. Knowledge obtained through this program may be applied to the design of improved vaccines and immunotherapies to combat infections or treat/prevent immune-mediated diseases in this vulnerable population. Due Date: June 4, 2021. 

NOSIs

  • You can learn more about NOSI’s in this quick 5 minute video.
  •  
NOT-TR-20-011
Notice of Special Interest (NOSI): Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Heath Need
​NCATS
CTSA (CTRI) award specific. PA-20-272 for UL1, U01, and R21 awards; PAR-19-099 for U01 specific awards; PAR-19-100 for R21 specific awards; PAR-19-337 for UL1 specific awards. 
  • Update: NOT-TR-20-018 expands the eligibility and activity codes to include U24 parent awards.
Due Date: varies per award mechanism and FOA. See NOSI. 
​NOT-AG-20-022
Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)
​NIA
​Administrative supplement work that is proposed through PA-20-272 must be within the general scope of the research or training that is already supported. Applications that involve a change in scope (e.g., the addition of human subjects to a grant that has not been previously so coded and approved, the addition of vertebrate animals to a grant that has not been previously so coded and approved) must apply through PA-18-935. An FAQ page was created to assist those interested in applying to this NOSI. It can be found hereDue Date: applications will be accepted on a rolling basis from April 6, 2020 through May 1, 2021.
​NOT-TR-20-016
Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus
​NCATS
​Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent: PA-20-272Due Date: applications will be accepted on a rolling basis from May 15, 2020 through January 25, 2022.
​NOT-MH-20-047
​Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel Coronavirus
​NIMH
NIA
NIAAA
NIMHD
ODP
Administrative supplement work that is proposed through PA-20-272 must be within the general scope of the research or training that is already supported. Applications that involve a change in scope (e.g., the addition of human subjects to a grant that has not been previously so coded and approved, the addition of vertebrate animals to a grant that has not been previously so coded and approved) must apply through PA-18-935Due Date: applications will be accepted on a rolling basis through April 15, 2021.
​NOT-TR-20-017
Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research on the 2019 Novel Coronavirus
​NCATS
Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent: PA-20-135. Due Date: applications will be accepted on a rolling basis from May 15, 2020 to January 25, 2022.
​NOT-MD-20-019
Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities
​NIMHD
NIA
NIMH
​Administrative supplement work that is proposed through PA-20-272 must be within the general scope of the research or training that is already supported. Applications that involve a change in scope (e.g., the addition of human subjects to a grant that has not been previously so coded and approved, the addition of vertebrate animals to a grant that has not been previously so coded and approved) must apply through PA-18-935Due Date: applications will be accepted on a rolling basis from May 01, 2020 through May 01, 2021.
  •  NOT-MD-20-024Notice of Information for Date of Submission to NOT-MD-20-019 and NIMHD Consideration for FY Award informs that all applications received by 5:00 PM on July 15, 2020 will be considered for funding in FY2020. Applications to NIMHD which are received after 5:00 PM (local time of the applicant institution) on July 15, 2020 may be held for consideration in Fiscal Year 2021 and not be eligible for funding before October 2020
​NOT-ES-20-020
Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)
​NIEHS
​This replaced NOT-ES-20-015. Administrative supplement work that is proposed through PA-18-591 must be within the general scope of the research or training that is already supported. Applications that involve a change in scope (e.g., the addition of human subjects to a grant that has not been previously so coded and approved, the addition of vertebrate animals to a grant that has not been previously so coded and approved) must apply through PA-18-935. If you are applying for a new R21 grant that does not build off of an existing NIEHS grant, apply to RFA-ES-19-011.  Due Date: application Due Dates for all programs: May 1, 2020; June 1, 2020; July 1, 2020; August 3, 2020; September 1, 2020; October 1, 2020; November 2, 2020; December 1, 2020; January 4, 2021; February 1, 2021; March 1, 2021; April 1, 2021; May 3, 2021.
​NOT-AA-20-011
​Notice of Special Interest: Availability of Administrative Supplements and Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIAAA
​NIAAA
​Administrative supplement work that is proposed through PA-20-272 must be within the general scope of the research or training that is already supported. Applications that involve a change in scope (e.g., the addition of human subjects to a grant that has not been previously so coded and approved, the addition of vertebrate animals to a grant that has not been previously so coded and approved) must apply through PA-18-935Due Date: applications will be accepted on a rolling basis through April 15, 2021.
​NOT-DC-20-008
Notice of Special Interest (NOSI): NIDCD is Interested in Supporting Research on the Impact of COVID-19 on Mission Specific Sensory and Communication Disorders
​NIDCD
​Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice.
  •  PA-18-334 - NIDCD Clinical Trials in Communication Disorders (R01 Clinical Trial Required)
  •  PA-20-185- NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
  •  PA-20-184 – NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
  •  PA-20-196 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)
  •  PA-20-195 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
  •  PA-20-194 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
Due Date: This notice applies to due dates on or after October 5, 2020 and subsequent receipt dates through September 8, 2022
​NOT-OD-20-129
Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19) in Individuals with Down Syndrome for the INCLUDE Project
OD
NHLBI
NHGRI
NIA
NIAID
NIAMS
NICHD
NIDCD
NIDCR
NIDDK
NIEHS
NINDS
NIMHD
NCCIH
NCATS
ORIP
NCI
Administrative supplement work that is proposed through PA-20-272 must be within the general scope of the research or training that is already supported. Applications that involve a change in scope (e.g., the addition of human subjects to a grant that has not been previously so coded and approved, the addition of vertebrate animals to a grant that has not been previously so coded and approved) must apply through PA-18-935.Due Date: July 13, 2020, November 12, 2020, March 12, 2021, and July 12, 2021

​NOT-AI-20-059
Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Select Research Activities related to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)
​NIAID
Applications in response to this NOSI must be submitted using the Emergency Competitive Revision to Existing NIH Awards: PA-20-135 (or its subsequent reissued equivalents). Due Date: applications will be accepted on a rolling basis 07/02/2020 to 07/02/2021.
​NOT-AI-20-065
Notice of Special Interest (NOSI): Availability of Emergency Awards for Limited Clinical Trials to Evaluate Therapeutic and Vaccine Candidates Against SARS-CoV-2
​NIAID
Applications in response to this NOSI must be submitted using PAR-18-633 NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required) (or its subsequent reissued equivalents). Due Date: September 14, 2020; October 14, 2020November 14, 2020; December 14, 2020; January 14, 2021; February 14, 2021; March 14, 2021; April 14, 2021; May 14, 2021; June 14, 2021; July 14, 2021; ; August 14, 2021; and September 14, 2021.
​NOT-NS-20-051
Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements For Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System
​NINDS
​Applications for this initiative must be submitted using one of the following opportunity announcements or the subsequent reissued equivalent. PA-20-272 must be within the general scope of the research or training that is already supported. Applications that involve a change in scope (e.g., the addition of human subjects to a grant that has not been previously so coded and approved, the addition of vertebrate animals to a grant that has not been previously so coded and approved) must apply through PA-18-935Due Date: applications will be accepted on a rolling basis from April 15, 2020 to April 14, 2021
​NOT-MD-20-025
Notice of Special Interest (NOSI): Simulation Modeling and Systems Science to Address Health Disparities
NIMHD
NCI
NIDA
NLM
NIMH
NIAMS

The following NIH Offices may co-fund applications assigned to those I/Cs:
ODP
OBSSR
​Submit applications for this initiative using the following funding opportunity announcement (FOA) or any reissue of thid announcement through the expiration date of this notice:
  •  PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
​Due Date: this notice applies to due dates on or after October 5, 2020 and subsequent receipt dates through May 8, 2023. 
​NOT-HL-20-814
Notice of Special Interest (NOSI): The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome/Acute Lung Injury (ARDS/ALI)
​NHLBI
​Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcements through the expiration date of this notice:
  •  PA-20-183 Research Project Grant (Parent R01 Clinical Trial Required)
  •  PA-20-185 Research Project Grant (Parent R01 Clinical Trial Not Allowed)
Due Date: Applications will be accepted dates on or after October 5, 2020 and subsequent receipt dates through July 5, 2024 of reissued FOAs.

​NOT-AI-21-002
​Emergency Awards: Notice of Special Interest (NOSI) on Pan-Coronavirus Vaccine Development Program Projects
​NIAID
​Applications in response to this NOSI must be submitted using the following funding opportunity: PAR-20-072; NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed). Due Date: Applications will be received on two receipt dates: January 11, 2021 and June 11, 2021.

​NOT-TR-21-011
Notice of Special Interest (NOSI): Availability of Emergency Administrative Supplements to Clinical and Translational Science Award (CTSA) Program Awards to Address 2019 Novel Coronavirus Disease (COVID-19) Public Health Needs
​NCATS
​​CTSA (CTRI) award specific. Applications for this initiative must be submitted using the following opportunity announcements or the subsequent reissued equivalent: PA-20-272.  ​Due Date:  Applications will be accepted immediately and on a rolling basis through June 1, 2021.
​NOT-MD-21-008
Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities
​NCI
NHLBI
NIAAA
NIAID
NIAMS
NIDA
NIDCR
NIMH
NINR

The following NIH Offices may co-fund applications assigned to those I/Cs:
OBSSR
ODP
ORWH
NIMHD
​Applications for this initiative must be submitted using the following opportunity announcements or the subsequent reissued equivalent:
  •  PA-20-183 - Research Project Grant (Parent R01 Clinical Trial Required)
  •  PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
Due Date: The first available due date is Feburary 5, 2021. Applications can be submitted through January 7, 2022. 

​NOT-MH-21-120
Notice of Special Interest: Administrative Supplements for COVID-19 Impacted NIMH Research
NIMH
​Applications for this initiative must be submitted using the following opportunity announcements or the subsequent reissued equivalent: PA-20-272. ​Due Date:  Applications will be accepted for due dates on or after January 5, 2021 with rolling receipt through June 1, 2023.
​NOT-DA-20-084
Notice of Special Interest (NOSI): Effects of smoking and vaping on the risk and outcome of COVID-19 infection
​NIDA
​​Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcements through the expiration date of this notice:
  •  PA-20-183 - NIH Research Project Grant (Parent R01 Clinical Trial Required)
  •  PA-20-200 - NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
  •  PA-20-195 - NIH Exploratory/Developmental Research Grant (Parent R21Clinical Trial Not Allowed)
Due Date: Applications will be accepted for due dates on or after January 7, 2021 and subsequent receipt dates through September 8, 2024.
​NOT-NS-21-037
Notice of Special Interest: Impact of COVID-19 on Dementia Risk, Progression and Outcomes in ADRD Populations
​NINDS
Applications for this initiative must be submitted using the following opportunity announcements or the subsequent reissued equivalent: PA-20-272.  ​Due Date: May 5, 2021
​NOT-GM-21-032
​Notice of Special Interest (NOSI): Administrative Supplements to SEPA Awards to Develop Innovative Educational Resources to Address SARS-CoV-2 Vaccine Hesitancy
​NIGMS
Applications for this initiative must be submitted using the following opportunity announcements or the subsequent reissued equivalent: PA-20-272.  ​Due Date: April 23, 2021
​NOT-OD-21-071
Notice of Special Interest (NOSI): Administrative Supplements and Urgent Competitive Revisions for NIH Grants to Add or Expand Research Focused on Maternal Health, Structural Racism and Discrimination, and COVID-19
​OD
​​Applications for this initiative must be submitted using one of the following opportunity announcements or the subsequent reissued equivalent. PA-20-272 must be within the general scope of the research or training that is already supported. Applications that involve a change in scope (e.g., the addition of human subjects to a grant that has not been previously so coded and approved, the addition of vertebrate animals to a grant that has not been previously so coded and approved) must apply through PA-18-935.  Due Date: April 14, 2021
​NOT-GM-21-021
Notice of Special Interest (NOSI): Urgent Competitive Revisions to IDeA and NARCH Programs to Address SARS-CoV-2 Vaccine Hesitancy
​NIGMS
SGMRO
Applications for this initiative must be submitted using the following opportunity announcements or the subsequent reissued equivalent: PA-18-935.  Due Date: 4/30/2021
​NOT-TR-21-022
​Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions for the Clinical and Translational Science Award (CTSA) Program to Address COVID-19 Public Health Needs
​NCATS
CTSA (CTRI) award specific. Applications for this initiative must be submitted using the following opportunity announcements or the subsequent reissued equivalent PA-20-135Due Date: Applications will be accepted immediately and on a rolling basis through August 16, 2024.
​NOT-AR-21-012
Notice of Special Interest: Promoting Research on COVID-19 and Rheumatic, Musculoskeletal and Skin Diseases
​NIAMS
​​​​Submit applications for this initiative using one of the following funding opportunity announcements (FOAs), or any reissues of these announcements, through the expiration date of this NOSI:
  •  PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
  •  PA-20-195 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
  •  PAR-21-055 - Mechanistic Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)
  •  PAR-21-054 - Mechanistic Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)
  •  PAR-21-053 - Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed) 
Due Date: Applications will be accepted for due dates on or after February 5, 2021 and subsequent receipt dates through November 18, 2021.
​NOT-DA-21-011
Notice of Special Interest (NOSI): Effects of smoking and vaping on the risk and outcome of COVID-19 infection
​NIDA
​​​Submit applications for this initiative using one of the following funding opportunity announcements (FOAs), or any reissues of these announcements, through the expiration date of this NOSI:
  •  PA-20-184 - Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
  •  PA-20-183 - Research Project Grant (Parent R01 Clinical Trial Required)
  •  PA-20-200 - NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
  •  PA-20-195 - NIH Exploratory/Developmental Research Grant (Parent R21 Clinical Trial Not Allowed)
  •  PA-20-194 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
  •  PA-20-196 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)
  •  PA-20-146 - NIDA Small Research Grant Program (R03 Clinical Trial Required)
Due Date: Applications will be accepted for due dates on or after June 5, 2021 and subsequent receipt dates through September 8, 2024.
​NOT-AG-21-015
Notice of Special Interest (NOSI): Aging-Relevant Behavioral and Social Research on Coronavirus Disease 2019 (COVID-19)
​NIA
​​Submit applications for this initiative using one of the following funding opportunity announcements (FOAs), or any reissues of these announcements, through the expiration date of this NOSI:
  •  PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
  •  PA-20-183 - NIH Research Project Grant (Parent R01 Clinical Trial Required)
  •  PA-20-184 - Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
  •  PA-20-195 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
  •  PA-20-194 - Parent R21 Exploratory/Developmental Grant, Clinical Trial Required
  •  PA-20-196 - Parent R21 Exploratory/Developmental Grant, Basic Experimental Studies with Humans Required
  •  PA-20-200 - NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
  •  PAR-19-374 - Complex Integrated Multi-Component Projects in Aging Research (U19 Clinical Trial Optional)
  •  PAR-19-314 - NIA Program Project Applications (P01 Clinical Trial Optional)
  •  PAR-19-070 - Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)
  •  PAR-19-071 - Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Not Allowed)
  •  PAR-20-070 - Research Infrastructure Development for Interdisciplinary Aging Studies (R21/R33 - Clinical Trial Optional)
Due Date: Applications will be accepted for due dates on or after March 4, 2021 and subsequent receipt dates through May 7, 2023.
​NOT-AG-21-016
Notice of Special Interest (NOSI): Neurological and Neurocognitive Sequelae from SARS-CoV-2 Infection and COVID-19 in Aging and Age-Related Neurodegeneration
​NIA
​Submit applications for this initiative using one of the following funding opportunity announcements (FOAs), or any reissues of these announcements, through the expiration date of this NOSI:
  •  PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
  •  PA-20-183 - NIH Research Project Grant (Parent R01 Clinical Trial Required)
  •  PA-20-184 - Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
  •  PA-20-195 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
  •  PA-20-194 - Parent R21 Exploratory/Developmental Grant, Clinical Trial Required
  •  PA-20-196 - Parent R21 Exploratory/Developmental Grant, Basic Experimental Studies with Humans Required
  •  PA-20-200 - NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
Due Date: Applications will be accepted for due dates on or after June 5, 2021 and subsequent receipt dates through May 7, 2023.
​NOT-GM-21-019
Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions for Modeling Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2
​NIGMS
​Applications for this initiative must be submitted using the following opportunity announcements or the subsequent reissued equivalent: PA-18-935.  Due Date: Applications will be accepted on a rolling basis from March 15, 2021 to December 15, 2021.
​NOT-DA-21-019
Notice of Special Interest (NOSI): Telehealth Strategies for Individuals with HIV and Substance Use Disorders
​NIDA
​​Submit applications for this initiative using one of the following funding opportunity announcements (FOAs), or any reissues of these announcements, through the expiration date of this NOSI:
  •  PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
  •  PA-20-183 - NIH Research Project Grant (Parent R01 Clinical Trial Required)
  •  PA-20-184 - Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
  •  PA-20-195 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
  •  PA-20-194 - Parent R21 Exploratory/Developmental Grant, Clinical Trial Required
  •  PA-20-196 - Parent R21 Exploratory/Developmental Grant, Basic Experimental Studies with Humans Required
  •  PA-20-200 - NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
Due Date: Applications will be accepted for due dates on or after May 7, 2021 and subsequent receipt dates through September 7, 2024.
​NOT-DA-21-017
Notice of Special Interest (NOSI): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19
​NIDA

​​​Submit applications for this initiative using one of the following funding opportunity announcements (FOAs), or any reissues of these announcements, through the expiration date of this NOSI:
  •  PA-20-183 - NIH Research Project Grant (Parent R01 Clinical Trial Required)
  •  PA-20-184 - Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
  •  PA-20-195 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
  •  PA-20-194 - Parent R21 Exploratory/Developmental Grant, Clinical Trial Required
  •  PA-20-196 - Parent R21 Exploratory/Developmental Grant, Basic Experimental Studies with Humans Required
Due Date: Applications will be accepted for due dates on or after May 5, 2021 and subsequent receipt dates through September 7, 2024. 
​NOT-AI-21-008
Notice of Special Interest (NOSI): Complement in Basic Immunology (CIBI)
​NIAID
​S​ubmit applications for this initiative using one of the following funding opportunity announcements (FOAs), or any reissues of these announcements, through the expiration date of this NOSI:
  •  PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
  •  PA-20-195 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
Due Date: Applications will be accepted for due dates on or after June 5, 2021 and subsequent receipt dates through January 7, 2023.
​NOT-DA-21-018
Notice of Special Interest (NOSI): Long-Term Neurocognitive Consequences of COVID-19 in Individuals Living with HIV and Substance Use Disorders
​NIDA
S​ubmit applications for this initiative using one of the following funding opportunity announcements (FOAs), or any reissues of these announcements, through the expiration date of this NOSI:
  •  PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
  •  PA-20-183 - NIH Research Project Grant (Parent R01 Clinical Trial Required)
  •  PA-20-184 - Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
  •  PA-20-195 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
  •  PA-20-194 - Parent R21 Exploratory/Developmental Grant, Clinical Trial Required
  •  PA-20-196 - Parent R21 Exploratory/Developmental Grant, Basic Experimental Studies with Humans Required
  •  PA-20-200 - NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
Due Date: Applications will be accepted for due dates on or after May 7, 2021 and subsequent receipt dates through September 7, 2024.